Weekly Medical Device News Roundup (May 11–17, 2026): IPO Filings, Product Approvals, and Strategic Advances

Recently, JD Health released its Q1 2026 performance, with revenue reaching 19.47 billion yuan, a year-on-year increase of 17.0%; Non-IFRS operating profit reached 1.94 billion yuan, a year-on-year increase of 48.0%; Non-IFRS net profit reached 1.87 billion yuan, a year-on-year increase of 6.0%. Strengthening the pharmaceutical supply chain advantage and promoting the "AI + supply chain" to empower the "medical, testing, diagnosis, and pharmaceutical" closed loop, all core operating indicators showed steady growth. In the field of "AI + medical devices," JD Health signed strategic cooperation agreements with brands such as Yuwell Medical, Cofoe Medical, and iFlytek Healthcare to deepen product intelligence upgrades and chronic disease management service innovation. Additionally, JD Health is accelerating the application of the JoyInside smart interconnection system in elderly care scenarios, planning to integrate millions of medical devices into the system, covering core elderly care categories such as wheelchairs, care beds, and health monitoring, collaborating with 10 leading brands to build a service ecosystem. Following this positive news, JD Health's stock price rose over 6% post-results.

Recently, Sanyou Medical established Hangzhou Xingyun Gui Intelligent Medical Technology Co., Ltd., with an 80% stake, to further invest in the intelligent orthopedic robot field and move towards autonomous and physical operations. The company will integrate advanced technologies such as the Chunfeng Huayu orthopedic surgical robot and Shuimu Tianpeng ultrasonic osteotome to explore the application of AI in innovative vertical large models for orthopedic therapies. Previously, Chunfeng Huayu, incubated and invested by Sanyou Medical, focused on the R&D and manufacturing of spinal surgical robots. Its product features a three-arm structural design, supports Level IV surgeries, has completed clinical cases in Canada, and plans to expand into multiple fields in the future. The global orthopedic surgical robot market size continues to grow and is expected to reach 56.7 billion yuan by 2030. The domestic market in China shows even more significant growth, with a projected annual compound growth rate of 82.8% over the next five years. Moreover, there is enormous potential for increasing the penetration rate of robot-assisted joint replacement surgeries in China.

On May 8, 2026, the conference on "Standards Leading the High-Quality Development of New Rehabilitation Productivity" was held in Shanghai, attended by numerous renowned scholars. He Yongzheng, Chairman of Xiangyu Medical, engaged in in-depth discussions with experts and scholars on topics such as standards leadership, sharing the company's experience in standardization construction, brain-computer interface technology transformation, and intelligent rehabilitation equipment R&D. Xiangyu Medical has significant advantages in relevant standard formulation. At the conference, Xiangyu Medical, in collaboration with the Shanghai Rehabilitation Medical Association, established the "Intelligent Rehabilitation and Brain Science Transformation Research Center" to accelerate the clinical transformation of scientific research achievements and the commercial implementation of cutting-edge technologies. Six major clinical rehabilitation project teams were also collectively inaugurated and signed agreements. This collaboration represents a strategic initiative by Xiangyu Medical to deepen its strategy of "Standards Leadership and Technology Empowerment." In the future, the company will continue to be driven by innovation, deepen its industrial ecosystem layout, promote the construction of standard systems, and contribute to the high-quality development of China’s rehabilitation medical industry.

Mindray Medical(300760.SZ) announced on May 11 that, in accordance with the requirements of the Hong Kong Stock Exchange, it had updated its listing application on May 11, 2026. The company simultaneously updated certain corporate information and financial data, and published the relevant updated documents on the Hong Kong Stock Exchange website on the same day. It should be noted that the application materials were prepared and published by the company in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange.Draft version, the information contained herein may be updated and revised as appropriate in the future.

Recently, Medtronic announced that Rogelio Blanco has officially taken office as Senior Vice President and Chief Operating and Supply Chain Officer, a position that had been vacant for about five months following the retirement of the previous executive. Blanco previously served as Executive Vice President and Global Operations and Supply Chain Officer at Eaton Corporation, bringing with him 33 years of career experience. This appointment marks his first entry into the medical device industry. Blanco's responsibilities include leading the strategy formulation and execution of Medtronic’s end-to-end operations and supply chain, covering manufacturing, supply chain, supply management, and other areas, which are highly similar to his duties at Eaton. He holds a degree in mechanical engineering and a Master of Business Administration in financial management, combining technical and financial expertise. Blanco’s arrival coincides with the start of Medtronic’s fiscal year 2027. He stated that he will listen, learn, and collaborate with various teams to support the company’s growth, aligning with the company’s efforts to enhance the reliability of its global operations.

Recently, Beijing released the Negative List for Data出境Management (2025 Edition) and supporting measures, expanding its scope to cover the entire provincial region. As a hub for high-end industries, Beijing Yizhuang has introduced five key measures to address challenges related to corporate data出境: leading the formulation of negative lists in the medical device and autonomous driving sectors, providing a basis for the iteration and optimization of municipal-level lists; establishing data cross-border service stations to support numerous enterprises and boost foreign investment confidence; creating a joint assessment mechanism to closely monitor risks across the entire chain; introducing targeted policies with financial incentives to encourage corporate compliance; and building a dedicated cross-border operational platform, planning a trusted cross-border data space, and setting up special channels. Beijing Yizhuang will also broaden the policy's coverage, establish service windows in multiple industrial parks, support pilot initiatives by enterprises, ensure rapid policy implementation, and enable businesses to benefit sooner.

Recently, Bank of China released the "Action Plan to Support the Entire Chain of Innovation Development in the Biopharmaceutical Industry" in Shanghai. During the "15th Five-Year Plan" period, it will provide comprehensive financial support of no less than 1 trillion yuan for the entire biopharmaceutical industry chain. The annual growth rate of new credit lines will exceed the industry average by more than 10 percentage points, with a focus on innovative small and medium-sized enterprises. Bank of China will focus on cultivating more than 5 leading enterprises and over 50 specialized, refined, distinctive, and innovative enterprises as well as hidden champions. More than 70% of newly credited enterprises will be innovative small and medium-sized enterprises. The bank will establish a regular communication mechanism with national ministries and commissions, focusing on increasing investment in the four core agglomeration areas; creating a "1+4" product and service system to address pain points in innovative financing; relying on the "single-point access, global response" service mechanism to build an entire chain service system around pharmaceutical companies' overseas expansion needs, offering products such as cross-border mergers and acquisitions, overseas direct loans, and providing cross-border compliance consulting to enhance the international competitiveness of the industry.

Hainan Introduces 20 Measures to Support the Development of Class II Innovative Medical Device Industry

Recently, the Liaoning Provincial Medical Products Administration issued the "Notice on the Implementation Plan for the 'Spring Rain Action' of Clinical Innovation Achievements Transformation in Medical Devices," aligning with the three-year action plan of the National Medical Products Administration. This initiative establishes a full-chain mechanism covering project solicitation and screening — matching and alignment — coaching and cultivation — transformation and implementation. The plan calls for clinical innovation projects from medical institutions across the province, focusing on selecting high clinical value achievements with feasible transformation potential. A platform for medical-engineering collaboration will be built to promote two-way matching between medical institutions and enterprises while dynamically managing projects. Key projects will receive comprehensive guidance through the entire process, including registration applications, clinical trials, review, and approval, and will be included in the special review and priority registration channels for innovative Class II medical devices within the province, accelerating the market entry process. Additionally, central-local cooperation will be strengthened, approval services optimized, and the industrial ecosystem cultivated to transform clinical ideas into safe and effective medical device products, supporting the high-quality development of Liaoning's medical device industry and the construction of a Healthy Liaoning.

On May 15, 2026, the Center for Medical Device Evaluation of the National Medical Products Administration released the "Public Notice of the Review Results for Special Examination of Innovative Medical Devices Applications (No. 8, 2026)." Eight medical device projects are proposed to enter the special examination process for innovative medical devices ("Green Channel"), and are currently under public notice. These eight products are: Acute Aortic Syndrome CT Plain Scan Image Triage Assistance Software by Alibaba's DAMO Academy (Beijing); Brain Tumor MRI Image-Assisted Diagnosis Software by Fuying (Shanghai) Medical; Degradable Magnesium Metal Bone Screw by Suzhou Zhuoqia Medical; Microsurgery Control System by Guangzhou Deep Medical Devices; Mycobacterium Tuberculosis Drug Resistance Gene Mutation Detection Kit by Nanjing Difly Medical Devices; Visible Liquid Embolic Agent by Zhiyuan Baimai (Zhejiang); Thrombectomy Cerebral Protection Device by Intellizon Medical (Shanghai); Heparin-Coated Artificial Blood Vessel by Shengna Technology (Shanghai). The public notice period is from May 15 to May 29.